Covered recipient · General Payments record
ELIZABETH M ANDEKIAN
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2023–2024
$5,478.31
- Reported across 16 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $3,600.00 | 1 |
| Travel and Lodging | $1,159.96 | 3 |
| Food and Beverage | $609.71 | 11 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $5,162.99 | 9 |
| Genentech USA, Inc. | $86.66 | 1 |
| PFIZER INC. | $55.53 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $23.57 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.09 | 1 |
| Novo Nordisk AS | $19.83 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $23.57 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086366421 | CMS |
| Genentech USA, Inc. | $86.66 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133156654 | CMS |
| GENZYME CORPORATION | $120.27 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139965827 | CMS |
| GENZYME CORPORATION | $673.21 | 03/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1139965863 | CMS |
| GENZYME CORPORATION | $263.35 | 03/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1139965865 | CMS |
| GENZYME CORPORATION | $223.40 | 03/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1139965867 | CMS |
| GENZYME CORPORATION | $78.47 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139965869 | CMS |
| GENZYME CORPORATION | $46.43 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139965871 | CMS |
| GENZYME CORPORATION | $65.00 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139965873 | CMS |
| GENZYME CORPORATION | $92.86 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139965875 | CMS |
| GENZYME CORPORATION | $3,600.00 | 03/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1139965877 | CMS |
| Novo Nordisk Inc | $19.83 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100605744 | CMS |
| PFIZER INC. | $27.21 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131597312 | CMS |
| PFIZER INC. | $28.32 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131597316 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.09 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137706453 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.